公开(公告)号：EP1627873A4

公开(公告)日：2007-12-05

申请号：EP04735405

申请日：2004-05-28

Applicant: NEW IND RES ORGANIZATION

Inventor： OISHI YOSHITAKA ,  KAWANO SHIGEKATSU ,  YOKOMIZO TAKEHIKO

IPC: C07D307/86 ,  A61K31/343 ,  A61K31/36 ,  A61K31/422 ,  A61K31/427 ,  A61K31/443 ,  A61K31/496 ,  A61K31/5377 ,  A61P11/06 ,  A61P29/00 ,  A61P37/00 ,  A61P37/08 ,  A61P43/00 ,  C07D307/80 ,  C07D307/81 ,  C07D307/82 ,  C07D307/85 ,  C07D405/06 ,  C07D407/12 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04

CPC classification number: C07D307/86 ,  C07D307/80 ,  C07D307/82 ,  C07D307/85 ,  C07D405/06 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04

Abstract: A benzofuran compound represented by the general formula (I): (I) (wherein the symbols are as defined in the description) or a pharmaceutically acceptable salt thereof. The compound is highly effective in leucotriene inhibition, BLT2 antagonistic inhibition, BLT2 blocking, allergy prevention/treatments, asthma prevention/treatments, and inflammation prevention/treatments and is useful as a preventive/therapeutic agent for allergic diseases, diseases such as asthma and inflammation, and other diseases.

公开(公告)号：JP2006225303A

公开(公告)日：2006-08-31

申请号：JP2005039888

申请日：2005-02-16

Applicant: NEW IND RES ORGANIZATION

Inventor： OISHI YOSHITAKA ,  KOIDA MASAO

IPC: C07D307/82 ,  A61K31/343 ,  A61K31/422 ,  A61K31/427 ,  A61K31/5365 ,  A61K31/675 ,  A61P3/14 ,  A61P19/00 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P29/00 ,  C07D413/12 ,  C07D417/04 ,  C07D498/04 ,  C07F9/6533

Abstract: PROBLEM TO BE SOLVED: To enlarge the selection range of treatment by diversifying preventive agents or therapeutic agents of bone metabolism disorder (e.g. osteoporosis, arthritis, chronic arthrorheumatism, arthropathia, osteoarthropathy, Paget's disease, Bechterew's disease and hypercalcemia) by providing a highly safe new-type estrogen-substitutional drug (nonhormonal remedy) having physical restoration activities of the bone similar to the estrogen. SOLUTION: The composition for preventing or treating the bone metabolism disorder contains a compound represented by formula (I) (wherein, each symbol is defined specifically) or a pharmaceutically acceptable salt thereof, or a compound represented by formula (X) (wherein, each symbol is defined specifically) or a pharmaceutically acceptable salt thereof. COPYRIGHT: (C)2006,JPO&NCIPI